Skip to main content
Log in

Comment on: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer

  • Correspondence
  • Published:
Prostate Cancer and Prostatic Diseases Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Cheng S, Prieto-Dominguez N, Yang S, Connelly ZM, StPierre S, Rushing B, et al. The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer. Prostate Cancer Prostatic Dis. 2020;23:661–9.

    Article  CAS  Google Scholar 

  2. Yang M, Li J, Li N, Guo H Re. The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer. Prostate Cancer Prostatic Dis. 2021. Epub ahead of print.

  3. Lee HC, Ou CH, Huang YC, Hou PC, Creighton CJ, Lin YS, et al. YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer. Oncogene. 2021;40:2407–21.

    Article  CAS  Google Scholar 

  4. Kuser-Abali G, Alptekin A, Lewis M, Garraway IP, Cinar B. YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. Nat Common 2015;1:8126.

  5. Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, et al. PARP inhibition suppresses GR-MYCN-CDK5-RB1-E2F1 signaling and neuroendocrine differentiation in castration-resistant prostate cancer. Clin Cancer Res. 2019;25:6839–51.

    Article  CAS  Google Scholar 

  6. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014;158:171–84.

    Article  CAS  Google Scholar 

  7. Giordano F, Naimo GD, Nigro A, Romeo F, Paolì A, De Amicis F, et al. Valproic acid addresses neuroendocrine differentiation of LNCaP cells and maintains cell survival. Drug Des Devel Ther. 2019;13:4265–74.

    Article  CAS  Google Scholar 

  8. Dicken H, Hensley PJ, Kyprianou N. Prostate tumor neuroendocrine differentiation via EMT: the road less traveled. Asian J Urol. 2019;6:82–90.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

Construction of the manuscript: QL; BP. Written of the manuscript: BP; YS. Modification of the manuscript: QL; JW.

Corresponding author

Correspondence to Qinglong Li.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peng, B., Sun, Y., Wu, J. et al. Comment on: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer. Prostate Cancer Prostatic Dis 25, 373–374 (2022). https://doi.org/10.1038/s41391-021-00453-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41391-021-00453-x

  • Springer Nature Limited

Navigation